Summary:
A Phase 3, Randomized, Doubleblind,
Placebo-controlled Study to Evaluate the
Efficacy and Safety of Rimegepant in Migraine
Prevention
Qualified Participants Must:
Age of onset of migraines prior to 50 years of age
Qualified Participants May Receive:
Compensation for time and travel